As per this study, the Global Plasma Protein Therapeutic Market was valued USD 29.2 BN (by revenue) in 2022 and is anticipated to reach USD 50.55 BN by 2030 with a CAGR of 7.1%.
Plasma protein therapeutic comprises of plasma-derived and recombinant analog therapies. These involve the treatment of various rare, life-threatening, chronic and genetic diseases. Some of the diseases that can be treated by using plasma protein therapeutic include bleeding disorders, immune deficiencies, pulmonary disorders, neurological disorders, shock and trauma, liver cirrhosis and infectious diseases such as tetanus, hepatitis, and rabies. Immunoglobulins, albumin, coagulation factors, and alpha-1 proteinase inhibitor are types of plasma protein therapeutic.
Market Dynamics
The increasing applications of plasma proteins in the pharmaceutical industry are driving market growth. Additionally, growing expenditure in the healthcare industry along with the introduction of new plasma-based therapies is further fuelling market growth. On the other hand, slower approval procedure and implementation of stringent regulation policies may restrict market growth. Whereas, increasing demand for plasma-based therapies in emerging economies is expected to create potential opportunity during the forecast period.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of plasma protein therapeutic.
Market Segmentation
The broad plasma protein therapeutic market has been sub-grouped into type and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Product
- Albumin
- Immunoglobulin
- Plasma-derived Factor VIII
- Others
By Application
- Hemophilia
- Primary Immunodeficiency Disorder (PIDD)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Others
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for plasma protein therapeutic in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Plasma Protein Therapeutic Market Share by Region (Representative Graph)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the plasma protein therapeutic market include CSL, Grifols, S.A, Takeda, Octapharma AG, Biotest AG, Kedrion S.p.A. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.